相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study
Craig F. Donatucci et al.
BJU INTERNATIONAL (2011)
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)
J. Curtis Nickel et al.
BJU INTERNATIONAL (2011)
Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial
Hartmut Porst et al.
EUROPEAN UROLOGY (2011)
The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
Marc R. Theoret et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study
Claus G. Roehrborn et al.
EUROPEAN UROLOGY (2010)
Effect of Dutasteride on the Risk of Prostate Cancer.
Gerald L. Andriole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
5α-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction
Roger S. Rittmaster
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia
R. Wurzel et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2007)
DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells
H Le et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
Discovery and clinical development of dutasteride, a potent dual 5 alpha-reductase inhibitor
Stephen V. Frye
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2006)
Dihydrotestosterone and the prostate:: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia
G Andriole et al.
JOURNAL OF UROLOGY (2004)
Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia
F Debruyne et al.
EUROPEAN UROLOGY (2004)
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
JD McConnell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride
J Barkin et al.
EUROPEAN UROLOGY (2003)
Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma
J Luo et al.
PROSTATE (2003)
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial
RS Kirby et al.
UROLOGY (2003)
5 alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium
LN Thomas et al.
JOURNAL OF UROLOGY (2003)
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
CG Roehrborn et al.
UROLOGY (2002)
Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia
G Bartsch et al.
WORLD JOURNAL OF UROLOGY (2002)
分享论文
